3,4-二氢咪唑并[4,5-b]吡啶-5-酮 | 28279-48-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 3,4-二氢咪唑并[4,5-b]吡啶-5-酮
• 英文名称: 1,4-dihydro-imidazo[4,5-b]pyridin-5-one
• 英文别名: 1,4-Dihydro-imidazo[4,5-b]pyridin-5-on；3,4-Dihydroimidazo[4,5-b]pyridin-5-one；1,4-dihydroimidazo[4,5-b]pyridin-5-one
• CAS: 28279-48-3
• 化学式: C₆H₅N₃O
• mdl: MFCD22194580
• 分子量: 135.125
• InChiKey: KTIHRQBDCJLDQX-UHFFFAOYSA-N

物化性质

• 熔点：
  311-313 °C (decomp)
• 沸点：
  593.1±50.0 °C(Predicted)
• 密度：
  1.443±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.8
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为产物：
  描述：

  3H-咪唑并[4,5-b]吡啶-5-胺 生成 3,4-二氢咪唑并[4,5-b]吡啶-5-酮
  参考文献：
  名称：

  Graboyes; Day, Journal of the American Chemical Society, 1957, vol. 79, p. 6421,6423,6424

  摘要：

  DOI：

文献信息

• Fused ring 4-oxopyrimidine derivative
  申请人：Nagase Tsuyoshi

  公开号：US20050182045A1

  公开（公告）日：2005-08-18

  The present invention provides a compound represented by formula (I) below, or a pharmaceutically acceptable salt thereof, which, having histamine H3 receptor antagonist or inverse agonist activity, is useful in the prophylaxis or therapy of metabolic diseases, circulatory diseases, or nervous system diseases. [where, for example, Ar is a divalent group formed by eliminating two hydrogen atoms from benzene, X 1 is a nitrogen atom, sulfur atom or oxygen atom, R 1 is a 5- to 6-membered heteroaryl group, Ring A is a 5- to 6-membered heteroaryl ring, R 2 and R 3 are amino groups or alkylamino groups, and X 2 is represented by formula (II): (where R 4 and R 5 are lower alkyl groups, and n is an integer from 2 to 4).]

  本发明提供以下公式（I）所表示的化合物或其药学上可接受的盐，具有组织胺H3受体拮抗剂或逆激动剂活性，在代谢性疾病、循环系统疾病或神经系统疾病的预防或治疗中有用。【其中，例如，Ar是通过从苯中消除两个氢原子形成的二价基团，X1是氮原子、硫原子或氧原子，R1是5-至6-成员杂芳基团，环A是5-至6-成员杂芳基环，R2和R3是氨基或烷基氨基，X2由以下公式（II）表示：（其中R4和R5是较低烷基基团，n是从2到4的整数）。】
• Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
  申请人：——

  公开号：US20020183324A1

  公开（公告）日：2002-12-05

  The present application describes monocyclic or bicyclic carbocycles and heterocycles and derivatives thereof of Formula I: 1 or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

  本申请描述了单环或双环碳环和杂环以及其衍生物的化合物I的公式，或其药用可接受的盐形式，这些化合物对于Xa因子的抑制剂具有用处。
• [EN] 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS<br/>[FR] DÉRIVÉS 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL UTILES DANS LE TRAITEMENT DE TROUBLES DU RÉCEPTEUR GPR81
  申请人：ARENA PHARM INC

  公开号：WO2010030360A1

  公开（公告）日：2010-03-18

  The present invention is directed to certain 3H-imidazo[4,5-b]pyridin-5-ol derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the GPR81 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of GPR81 associated disorders, for example, dyslipidemia, atherosclerosis, atheromatous disease, hypertension, coronary heart disease, stroke, insulin resistance, impaired glucose tolerance, type 2 diabetes, syndrome X, obesity, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type 1 diabetes and acne.

  本发明涉及某些Formula（Ia）的3H-咪唑[4,5-b]吡啶-5-醇衍生物及其药学上可接受的盐，这些衍生物具有有用的药理特性，例如作为GPR81受体的激动剂。本发明还提供了含有本发明化合物的药物组合物，以及使用本发明化合物和组合物治疗GPR81相关疾病的方法，例如脂质代谢异常、动脉粥样硬化、动脉粥样病、高血压、冠心病、中风、胰岛素抵抗、糖耐量受损、2型糖尿病、X综合征、肥胖、牛皮癣、类风湿性关节炎、克罗恩病、移植排斥反应、多发性硬化症、全身性红斑狼疮、溃疡性结肠炎、1型糖尿病和痤疮。
• Nitrogenous fused heteroaromatic ring derivative
  申请人：Takahashi Toshiyuki

  公开号：US20070167453A1

  公开（公告）日：2007-07-19

  The invention provides a compound or its pharmaceutically-acceptable salt of formula wherein A 1 is a hydrogen, etc.; j and k are 0 or 1; is a double bond, etc.; is a double bond, etc.; one of W 1 and W 2 is E-O—W, etc., and the other is a hydrogen atom, etc.; E is a divalent group derived from a benzene ring, etc., by removing two hydrogen atoms therefrom; W is a group of formula (II-1): which has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for prevention or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

  本发明提供以下化合物或其药学上可接受的盐：其中A1为氢等；j和k为0或1；为双键等；为双键等；W1和W2中的一个为E-O-W等，另一个为氢原子等；E为由苯环衍生的二价基团，通过从中去除两个氢原子而得到；W为式（II-1）的基团：其具有组织胺H3受体拮抗作用或组织胺H3受体反向激动剂作用，并且对于预防或治疗代谢系统疾病、循环系统疾病或神经系统疾病是有用的。
• Quinazoline Derivative
  申请人：Mizutani Takashi

  公开号：US20080275069A1

  公开（公告）日：2008-11-06

  This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R 1 represents a lower alkyl group et al; R 2 and R 3 are same and different and represents hydrogen atm et al; R 4 represents the substituent of the formula (I) et al; X 1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中R1代表较低的烷基等；R2和R3相同或不同，分别代表氢原子等；R4代表式（I）的取代基等；X1代表NH、O或S；Y代表N或C；Ar是由芳基衍生的二价取代基等，通过去除其中的两个氢原子而得到；环A表示5-或6-成员杂芳基基团；这些化合物具有组胺H3受体拮抗作用或组胺H3受体反向激动剂作用，并且对于预防或治疗代谢系统疾病、循环系统疾病或神经系统疾病是有用的。